Novo Nordisk's newer drug amycretin is reported to produce significant weight loss. Details are thin, so tap through for the trial data.
Recap by typeshit. Full story at BusinessWorld Online.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
Barzilai highlights trial results on retatrutide in adults with sleep apnea and obesity or overweight, a new use being tested for Lilly's drug.
The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
Researchers tracked spending on drinks while out and found a sharp drop among people taking GLP-1 medications.
Refused by a doctor for not being overweight, she got doses from an acquaintance and spent two days ill. She writes about why she wanted to be thinner anyway.
UTHealth Houston researchers found 11% lower odds of major heart complications, but the real gap works out to about one fewer event per 1,000 patients.
Loading…